Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Size Shifted, And What Is the Outlook Through 2034?
The market size for adeno-associated virus (avv) vectors utilized in gene therapy has experienced swift expansion lately, with projections showing it escalating from $2.7 billion in 2024 to a substantial $3.16 billion in 2025, indicating a compound annual growth rate (CAGR) of 16.7%. This robust growth in the historical period can be credited to factors such as heightened investment in gene therapy studies, increasing embracement of gene editing technologies, amplified cases of genetic disorders and unfulfilled medical requirements, growing demand for targeted treatment approaches, and heightened cooperative efforts among biotech enterprises and academic research institutions.
Expectations for the Adeno-associated virus (AVV) vectors in gene therapy market predict a significant expansion in the coming years. It is forecasted to reach $6.09 billion by 2029, with a compound annual growth rate (CAGR) of 17.6%. The predicted expansion in this period can be ascribed to several factors like the continual advancements in AAV capsid engineering, an increased emphasis on precision medicine, escalating investments in genetic research and biotechnology, rising number of gene therapy clinical trials and approvals, and a higher demand for personalized treatments. Key trends projected to shape this period include the evolution of artificial intelligence in AAV capsid engineering, the creation of hybrid AAV vectors for larger genetic payloads, breakthroughs in bispecific antibody-mediated AAV targeting, progress in scalable AAV production and purification technologies, and the establishment of versatile AAV platforms that aid a range of viral vectors.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp
What External and Internal Drivers Are Contributing to the Growth of theAdeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
The growing emphasis on gene-oriented therapies is anticipated to stimulate the expansion of the adeno-associated virus (AAV) vectors within the gene therapy market. Gene-oriented therapies are targeted interventions that alter or intervene with genes to either prevent, manage, or entirely cure diseases on a molecular level. The surge in genetic research advancements highlights the intensifying focus on devising gene-oriented therapies because they improve the accuracy and efficacy of gene editing techniques. Adeno-associated virus (AAV) vectors used in gene therapy facilitate the construction of gene-oriented therapies by effectively and securely transporting therapeutic genes into the target cells, all thanks to their limited immunogenicity and their capacity to guarantee long-term gene expression. For example, IQVIA, a US-based company that offers enhanced analytics and technology solutions for the life science sector, reported that in 2023, worldwide expenditure on cell and gene therapies hit $5.9 billion, denoting a 38% upsurge from 2022. Therefore, the escalating emphasis on devising gene-oriented therapies is fostering the expansion of the adeno-associated virus (AAV) vectors market.
What Segment Types Define the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Structure?
The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –
1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy
2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Scale of Operation: Preclinical, Clinical, Commercial
4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area
Subsegments:
1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders
2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering
3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
Leading corporations in the adeno-associated virus (AAV) vectors sector of gene therapy are prioritizing innovative advancements. This includes pioneering tailored vector diversity to promote assay versatility, with the aim of improving targeted tissue precision, boosting therapeutic efficacy, and hastening the creation of customized gene therapies across various indications. Tailored vector diversity for assay versatility implies employing a range of AAV serotypes or structures to support numerous analytical tests and therapeutic uses. For example, Charles River Laboratories, an American pharmaceutical company, released new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV) in May 2024. These materials are designed to meet the expanding demands of cell and gene therapy (CGT) development. This portfolio eases the transition from initial research to GMP-grade manufacturing and aids in standardizing procedures while enhancing consistency in viral vector production. This launch targets a prevalent hurdle in escalating CGT programs towards clinical and commercial readiness.
View the full report here:
What Is the Definition of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
Adeno-associated virus (AAV) vectors in gene therapy are advanced delivery tools that transport genetic material into cells to treat various genetic disorders. Their primary goal is to enable targeted, long-lasting therapeutic effects by correcting or modifying faulty genes. AAV vectors are valued for their safety, low immunogenicity, and ability to deliver genes to both dividing and non-dividing cells, supporting the development of precise and durable gene therapies that advance personalized medicine and transform the treatment of rare and inherited diseases.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24135
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
